Last reviewed · How we verify
Multiple Sclerosis
Approved treatments
- Solu-Cortef · Pfizer
- Zeposia · Bristol-Myers Squibb
Zeposia works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression. - Aubagio · Sanofi
Teriflunomide inhibits dihydroorotate dehydrogenase, reducing activated lymphocytes in the CNS. - Cortifoam · Pfizer
- Cortone
- Tysabri · Biogen Idec
Natalizumab blocks α4 integrins on leukocytes, preventing their adhesion to VCAM-1 and MAdCAM-1, reducing inflammation in MS and Crohn's disease. - Celestone Soluspan
- Decadron · Generic (originally Merck)
- fampridine · Biogen
- prednison · Wen Zhang
- Copaxone · University of California, Los Angeles
- Medrol · Generic (originally Upjohn/Pfizer)
Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions. - Pf-06700841 · Pfizer
- PF-06700841 45 mg · Pfizer
Unknown mechanism of action - Cortef · Generic (originally Merck/Upjohn)
- Copaxone · Teva
Copaxone works by modulating the immune system's response to reduce inflammation in the central nervous system. - Rodinolone
- Fampyra · Vestre Viken Hospital Trust
- Deltasone · Generic (originally Schering)
- Betametasone
Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system. - Cortisol · University of Zurich
- Prelone · Generic (originally Schering)
- Tysabri · University of Chicago
- prednisolon · Hannover Medical School
- Methylprednisolon · Leiden University Medical Center